title: Association of cortactin and fascin-1 expression in gastric adenocarcinoma: correlation with clinicopathological parameters.
abstract: Cortactin and fascin-1 are important factors in tumor progression. We tested the hypothesis that cortactin and fascin-1 expression correlates with clinicopathological parameters of gastric adenocarcinoma. Immunohistochemical analysis of cortactin and fascin-1 was done using tissue microarrays of 100 surgical specimens, including 20 well-differentiated, 20 moderately differentiated, and 60 poorly differentiated gastric adenocarcinomas. Among the 20 well-differentiated gastric adenocarcinomas, 15 cases (75%) showed negative or weak staining (1+); 5 cases (25%) had moderate (2+) or strong (3+) cortactin expression. Among the 60 poorly differentiated gastric adenocarcinomas, more than three-quarters of the cases (76.7%) had moderate or strong cortactin expression; 14 cases (23.3%) had weak staining. Of 20 well-differentiated gastric adenocarcinoma cases, 14 (70%) showed negative or weak staining of fascin-1, whereas nearly one-third (30%) had moderate or strong expression. Among the 60 poorly differentiated gastric adenocarcinomas, 32 (53.3%) exhibited moderate or strong fascin-1 expression; fewer than half of the cases showed negative or weak staining. Higher intensity of cortactin and fascin-1 staining correlated directly with more-advanced cancer stages (TNM) and inversely with survival rates. Our findings suggest the possibility that pharmacological inhibitors of cortactin and fascin-1 activity may slow down tumor progression and prolong survival time in patients with gastric adenocarcinomas.
authors.affiliation: Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Neihu, Taipei, Taiwan.
authors.forename: Wen-Chiuan
authors.initials: WC
authors.lastname: Tsai
authors.forename: Jong-Shiaw
authors.initials: JS
authors.lastname: Jin
authors.forename: Wei-Kuo
authors.initials: WK
authors.lastname: Chang
authors.forename: De-Chuan
authors.initials: DC
authors.lastname: Chan
authors.forename: Ming-Kung
authors.initials: MK
authors.lastname: Yeh
authors.forename: Shiou-Chih
authors.initials: SC
authors.lastname: Cherng
authors.forename: Li-Fan
authors.initials: LF
authors.lastname: Lin
authors.forename: Lai-Fa
authors.initials: LF
authors.lastname: Sheu
authors.forename: You-Chen
authors.initials: YC
authors.lastname: Chao
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D002352:Carrier Proteins / Q000096:biosynthesis*; D051356:Cortactin / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008840:Microfilament Proteins / Q000096:biosynthesis*; D009367:Neoplasm Staging; D013274:Stomach Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D046888:Tissue Array Analysis
chemical_list: D002352:Carrier Proteins; D051356:Cortactin; C502658:FSCN1 protein, human; D008840:Microfilament Proteins